Salix to share new Rifaximin data at AASLD’s Liver Meeting ™ 2021

LAVAL, QC, November 11, 2021 / PRNewswire / – Bausch Health Companies Inc. (NYSE / TSX: BHC) (“Bausch Health”) and its gastroenterology company, Salix Pharmaceuticals, (“Salix”), one of the world’s largest specialty pharmaceutical companies engaged in the treatment of gastrointestinal (GI) and hepatic diseases, today announced the presentation of two abstracts with new data on rifaximin at the Liver Meeting â„¢ 2021, organized by the American Association for the Study of Liver Diseases ( AASLD), which takes place virtually November 12-15, 2021.

The summaries available to participants registered on The Liver Meeting Digital Experience include:

• Bajaj, Jasmohan et al. “Rifaximin 40 mg Soluble Solid Dispersion Immediate-Release Tablets for Improving All-Cause Hospital Time / Decreased Mortality: A Subgroup Analysis of Demographic and Baseline Characteristics.”
• Volk, Michael et al. “Emergency Department Use in Cirrhosis and Hepatic Encephalopathy Patients Treated with Rifaximin and / or Lactulose: An Analysis of 2 Healthcare Claims Databases. ”

About XIFAXAN®
Indications
XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction of the risk of recurrence of overt hepatic encephalopathy (HE) in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults. ‘adult.

IMPORTANT SAFETY INFORMATION

• XIFAXAN is contraindicated in patients with hypersensitivity to rifaximin, to antimicrobial agents rifamycin, or to any of the components of XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
• Clostridium difficile-associated diarrhea (ACAD) has been reported with the use of almost all antibacterial agents, including XIFAXAN, and their severity can vary from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, continued use of antibiotics not directed against It’s hard may need to be discontinued.
• There is an increased systemic exposure in patients with severe hepatic impairment (Child-Pugh class C). Care should be taken when administering XIFAXAN to these patients.
• Caution should be taken when the concomitant use of XIFAXAN and P-glycoprotein (P-gp) and / or OATP inhibitors is required. Co-administration of cyclosporine, an inhibitor of P-gp and OATP, significantly increased systemic exposure to rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase systemic exposure to rifaximin.
• In clinical studies, the most common side effects of XIFAXAN were:
• HE (≥ 10%): peripheral edema (15%), nausea (14%), dizziness (13%), fatigue (12%) and ascites (11%)
• IBS-D (≥2%): Nausea (3%), ALT increased (2%)
• Changes in INR have been reported in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dosage adjustment of warfarin may be necessary.
• XIFAXAN can damage the unborn child. Inform pregnant women of the potential risk to the fetus.

To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please click here for full prescribing information.

About Salix
Salix Pharmaceuticals is one of the world’s largest specialty pharmaceutical companies engaged in the prevention and treatment of gastrointestinal diseases. For more than 30 years, Salix has authorized, developed and marketed innovative products to improve the lives of patients and provide healthcare providers with life-changing solutions for many chronic and debilitating diseases. Salix currently markets its product line to US healthcare providers through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists and primary care. Salix is ​​headquartered at Bridgewater, New Jersey. For more information about Salix, visit www.Salix.com and connect with us on Twitter and LinkedIn.

About Bausch Santé
Bausch Health Companies Inc. (NYSE / TSX: BHC) is a global company with a mission to improve people’s lives through our health care products. We develop, manufacture and market a range of pharmaceuticals, medical devices and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We live up to our commitments by building an innovative company dedicated to advancing global health. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn.

Forward-looking statements
This press release may contain forward-looking statements, which can generally be identified by the use of the words “expects”, “hopes”, “expects”, “intends”, “plans”, “should”, “Could”, “” would “,” could “,” believes “,” believes “,” potential “,” target “or” continuing “and variations or similar expressions. These statements are based on the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in the annual report. the most recent from Bausch Health Companies Inc. (Bausch Health) on Form 10-K and detailed from time to time in other documents filed by Bausch Health with the United States Securities and Exchange Commission and Canadian Authorities securities, which factors are incorporated herein by reference. They also include, but are not limited to, the risks and uncertainties caused by or related to the course of the COVID-19 pandemic, and the fear of this pandemic and its potential effects, including severity, duration. and the future impact are highly uncertain and cannot be predicted, and which may have a material negative impact on Bausch Health, including, but not limited to, the development times of its projects and costs (which may increase ). Readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health assumes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual results, except as required by law.

© 2021 Salix Pharmaceuticals or its subsidiaries.
The product XIFAXAN 550 mg and the brand XIFAXAN are licensed from Alfasigma SpA to Salix Pharmaceuticals or its subsidiaries.
SAL.0142.USA.21

SOURCE Bausch Health Companies Inc.

Related links

http://www.bauschhealth.com